Soluble ST2: A biomarker to monitor heart failure progression and treatment

Marin Nishimura; Justin Sharim; Yu Horiuchi; Olga Barnett; Nicholas Wettersten; Alan S Maisel

doi:10.4103/JCPC.JCPC_41_18

Users Online: 18

REVIEW ARTICLE

Year : 2018 | Volume : 7 | Issue : 4 | Page : 148-153

Soluble ST2: A biomarker to monitor heart failure progression and treatment

Marin Nishimura MD, ¹, Justin Sharim MD, ², Yu Horiuchi MD, ³, Olga Barnett MD, ⁴, Nicholas Wettersten MD, ¹, Alan S Maisel MD, ¹
¹ Division of Cardiovascular Medicine, University of California San Diego, San Diego, California, USA
² Department of Medicine, University of California, San Diego, California, USA
³ Division of Cardiovascular Medicine, Veterans Affairs Medical Center, San Diego, California, USA
⁴ Department of Cardiology, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

Correspondence Address:
Dr. Marin Nishimura
9500 Gilman Dr Mc 7411C La Jolla, California 92093-7411
USA

Source of Support: None, Conflict of Interest: None

Check

DOI: 10.4103/JCPC.JCPC_41_18

Measurement of cardiac biomarkers has become routine for the care of patients with heart failure (HF). While troponin and natriuretic peptides are well-entrenched in the guidelines, soluble ST2 (sST2) is a novel biomarker that has shown consistent performance and is ready for clinical use. Multiple studies support the use of sST2 in both acute and chronic HF for prognostication. We suggest a novel scheme to guide HF management based on ambulatory sST2 levels.

[FULL TEXT] [PDF]*

Table of Contents

Similar in PUBMED

Search Pubmed for

Search in Google Scholar for

Related articles

Citation Manager

Access Statistics

Reader Comments

Email Alert *

Add to My List *

* Requires registration (Free)

Article Access Statistics

Viewed	7569

Printed	264

Emailed	0

PDF Downloaded	733

Comments	[Add]

Cited by others	5